Purple Biotech Ltd

What they do

Purple Biotech Ltd. is a clinical-stage biopharmaceutical company focused on oncology drug development. The company operates through its majority-owned subsidiary TyrNovo and wholly owned subsidiaries FameWave and Immunorizon, which conduct research and development. Its activities include advancing product candidates through preclinical and clinical stages, with a pipeline centered on cancer treatments. The company is headquartered in Rehovot, Israel, and its ADSs trade on NASDAQ under the symbol PPBT.

Revenue drivers

• No approved products — The company has no commercial products, so it generates no revenue from product sales.
• Collaboration and licensing income — Potential future revenue from partnerships or licensing deals, though no specific agreements are detailed in the provided filing.
• Grant funding — May receive non-dilutive funding from government grants or similar programs, common for Israeli biotech firms, but no current figures are given.

Recent performance

The filing provides annual net income figures: $5.4 million in 2019, $28.7 million in 2020, and $17.8 million in 2021. These figures likely reflect non-operating items such as changes in fair value of warrants or other financing activities, as the company is a development-stage biotech with no product revenue. The filing is for fiscal year 2025, but the net income figures are from earlier years, suggesting the company has not reported recent operating profitability. The company had 1,858,911,801 ordinary shares outstanding, including one treasury share.

Strategy

The company is advancing its oncology pipeline through its subsidiaries, with a focus on developing novel therapies. It has made changes to its ADS ratio to maintain compliance with NASDAQ listing requirements, indicating a focus on capital markets management. The company continues to operate as a development-stage entity, investing in research and clinical trials. It also has a wholly owned subsidiary in Germany in the process of dissolution, suggesting portfolio rationalization.

Risks

• No approved products — The company has no commercial products and no revenue from product sales, making it dependent on future development and regulatory success.
• Clinical trial risk — As a clinical-stage biotech, its product candidates may fail in trials, leading to delays or abandonment.
• Financing risk — The company may need to raise additional capital to fund operations, and future dilutive offerings may be required.
• Subsidiary dissolution — Purple Biotech GmbH is in the process of dissolution, which may involve costs or indicate restructuring of operations.

Outlook

Management's stated direction is to continue developing its oncology pipeline aimed at bringing new therapies to market. The company has recently changed its ADS ratio, likely to maintain NASDAQ listing compliance, which suggests a focus on sustaining its public listing. Specific upcoming milestones or guidance are not provided in the filing excerpt.